Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.

Journal of Neuro-oncology
Isabel JiménezMarta Crespo

Abstract

Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood-brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib...Continue Reading

References

Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Mar 8, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Antonio SicaPaola Allavena
Sep 28, 2010·International Journal of Cancer. Journal International Du Cancer·Daniel VenetzMariagrazia Uguccioni
Jan 3, 2012·Biochemical Pharmacology·Joel G TurnerDaniel M Sullivan
Apr 11, 2013·Blood·James L RubensteinClifford Lowell
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 10, 2015·Experimental Hematology & Oncology·Arundhati DasDelong Liu
Jun 27, 2015·Neuropathology and Applied Neurobiology·T NakamuraK Ichimura
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albiruni R Abdul RazakAmit Mahipal
Jan 21, 2017·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Mariana N KerbauyJoachim Yahalom
Feb 23, 2017·Annual Review of Immunology·Marco Colonna, Oleg Butovsky
Mar 5, 2017·Immunological Reviews·Hanke L MatlungTimo K van den Berg
May 30, 2017·Cancer Cell·Michail S LionakisWyndham H Wilson
Jun 18, 2017·Cancer Discovery·Christian GrommesIngo K Mellinghoff

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
bioluminescence imaging
biopsy
flow cytometry

Software Mentioned

Living Image

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.